Posted: 12 June 2025
Chimeric Therapeutics Limited (ASX:CHM), an Australian leader in cell therapy, announced the receipt of $2,500,000 from Endpoints Capital under a funding facility secured against the anticipated FY25 Research and Development Tax Incentive (RDTI).
The funds were allocated to support the clinical trial pipeline and provide general working capital. This capital reinforced Chimeric’s financial position following a $6.6 million Placement, a $1 million Entitlement Offer, and $4 million in non-dilutionary funding announced in recent months.
The funding agreement with Endpoints Capital provided early access to a portion of the anticipated FY25 RDTI. The facility was secured against the anticipated FY25 RDTI from the Australian Taxation Office, with interest charged at a commercial rate. Repayment was timed to follow the anticipated receipt of the FY25 RDTI, due by 31 December 2025. The facility could be repaid at any time without penalty prior to this date, subject to a minimum interest period of 60 days.
The Australian Government RDTI program provided companies engaging in eligible activities with a refundable tax offset of up to 43.5%.
For more information, click here.
